Equity Details
Price & Market Data
Price: $1.60
Daily Change: +$0.02 / 1.25%
Daily Range: $1.54 - $1.63
Market Cap: $425,829,248
Daily Volume: 1,093,487
Performance Metrics
1 Week: -2.44%
1 Month: 8.84%
3 Months: 11.89%
6 Months: 20.30%
1 Year: 18.52%
YTD: -19.60%
About Autolus Therapeutics plc (AUTL)
Understand Autolus Therapeutics plc (AUTL)'s current market standing. Current price: 1.60, daily change: +$0.02 / 1.25%. Market cap: 425,829,248. Detailed performance for all periods.
Company Details
Employees: 752
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United Kingdom
Details
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.